Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Significant unmet treatment needs remain for patients with Dravet syndrome, a severe ... high-value disease-modifying medicines for rare genetic diseases globally, we aim to lead the treatment ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...

Its lead candidate, zorevunersen, is nearing Phase 3 trials for Dravet syndrome, a rare and debilitating epilepsy disorder. But the true opportunity and risk is whether Stoke's broader pipeline ...